Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models

Therapeutic peptides: Historical perspectives, current development trends, and future directions

(2018) Jolene L. Lau et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action

(2018) Caslin A. Gilroy et al.   JOURNAL OF CONTROLLED RELEASE

Integrated genomic and molecular characterization of cervical cancer

(2017)   NATURE

Functional precision cancer medicine—moving beyond pure genomics

(2017) Anthony Letai   NATURE MEDICINE

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

(2017) Grace R. Anderson et al.   Cell Reports

One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer

(2017) Kelli M. Luginbuhl et al.   Nature Biomedical Engineering

Targeting cell death signalling in cancer: minimising ‘Collateral damage’

(2016) Joanna L Fox et al.   BRITISH JOURNAL OF CANCER

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

Integrated genetic and pharmacologic interrogation of rare cancers

(2016) Andrew L. Hong et al.   Nature Communications

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers

(2016) Sonja C. Lueck et al.   Oncotarget

Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer

(2016) Marina Devetzi et al.   Scientific Reports

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

(2015) J. E. Allen et al.   CANCER RESEARCH

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

(2014) Luke A. Gilbert et al.   CELL

Getting TRAIL back on track for cancer therapy

(2014) J Lemke et al.   CELL DEATH AND DIFFERENTIATION

Combinatorial delivery of Crizotinib–Palbociclib–Sildenafil using TPGS-PLA micelles for improved cancer treatment

(2014) Duarte de Melo-Diogo et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis

(2014) M Ehrenschwender et al.   Cell Death & Disease

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

X-Linked Inhibitor of Apoptosis Protein – A Critical Death Resistance Regulator and Therapeutic Target for Personalized Cancer Therapy

(2014) Petra Obexer et al.   Frontiers in Oncology

A Unified Model for De Novo Design of Elastin-like Polypeptides with Tunable Inverse Transition Temperatures

(2013) Jonathan R. McDaniel et al.   BIOMACROMOLECULES

A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection

(2013) M. Amiram et al.   JOURNAL OF CONTROLLED RELEASE

Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2-Induced Apoptosis

(2013) J. S. Swers et al.   MOLECULAR CANCER THERAPEUTICS

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control

(2013) M. Amiram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Genetic Screens in Human Cells Using the CRISPR-Cas9 System

(2013) Tim Wang et al.   SCIENCE

TRAIL on trial: preclinical advances in cancer therapy

(2013) Daniel W. Stuckey et al.   TRENDS IN MOLECULAR MEDICINE

Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways

(2013) M van Dijk et al.   Cell Death & Disease

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc  receptor engagement

(2012) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

(2011) S. M. Schoenwaelder et al.   BLOOD

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

A public genome-scale lentiviral expression library of human ORFs

(2011) Xiaoping Yang et al.   NATURE METHODS

Recursive Directional Ligation by Plasmid Reconstruction Allows Rapid and Seamless Cloning of Oligomeric Genes

(2010) Jonathan R. McDaniel et al.   BIOMACROMOLECULES

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

(2010) D. P. McLornan et al.   CLINICAL CANCER RESEARCH

X Chromosome-linked Inhibitor of Apoptosis Regulates Cell Death Induction by Proapoptotic Receptor Agonists

(2009) Eugene Varfolomeev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

XIAP discriminates between type I and type II FAS-induced apoptosis

(2009) Philipp J. Jost et al.   NATURE

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

(2008) Kate Connolly et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma

(2008) O Ndozangue-Touriguine et al.   ONCOGENE